Tavapadon, an orally available small molecule being developed for Parkinson’s disease, was generally safe and eased motor symptoms within one month of being administered at either a fixed or flexible dose to adults with early-stage disease. It also reduced the risk of common side effects typically associated with similar classes…
News
A new study in juvenile zebra finches — a songbird species known for singing to attract mates — shows that mastering complex natural behaviors like singing depends on dopamine, a key signaling chemical that is lacking in the brains of people with Parkinson’s disease. The findings of this novel…
Vyalev (foscarbidopa and foslevodopa) demonstrated a favorable long-term safety and tolerability profile, along with sustained motor symptom control, in Parkinson’s disease patients who participated in the extension part of a Phase 3 trial (NCT03781167). Results from nearly two years of the extension study (NCT04379050) showed…
U.S. researchers have identified a novel way to block a protein known as DLK, or dual leucine-zipper kinase, that may offer a promising strategy to protect neurons from degeneration — which, the team notes, could pave the way for safer and more precise treatments for neurodegenerative conditions like Parkinson’s…
Arvinas has begun a Phase 1 clinical trial to test its investigational therapy ARV-102 in people with Parkinson’s disease, with Phase 1 data in healthy adults showing it was safe and worked as expected. ARV-102 is being developed for neurodegenerative conditions where the leucine-rich repeat kinase 2, or…
Spinal cord stimulation failed to improve walking ability despite multiple attempts in a small group of people with Parkinson’s disease who experienced freezing of gait — a symptom where the feet suddenly feel stuck and unable to move forward — according to the researchers running the study. The study…
Pretzel Therapeutics has launched a Phase 1 clinical trial to study PX578, a therapy designed to boost the function of mitochondria, the cell’s energy-producing powerhouses, and address conditions caused by faulty energy production. These include rare genetic conditions and neurodegenerative disorders like Parkinson’s and Alzheimer’s. The…
When used as a solo therapy, solengepras (CVN424) — an oral treatment being developed by Cerevance — was seen to lessen both functional and nonmotor symptoms in people with early, untreated Parkinson’s disease. That’s according to top-line results from the Phase 2 ASCEND trial (NCT06006247), which…
Nitrase Therapeutics’ NDC-0524, an antibody therapy for Parkinson’s disease, significantly reduced alpha-synuclein aggregation and spreading in mouse models of the disease, according to preclinical data released by the company. The antibody targets nitrated alpha-synuclein, a misfolded form of the protein that forms toxic clumps in dopaminergic neurons, the nerve cells…
The flamingo exercise — training to stand on one leg, as the bright-pink wading birds often do — was shown to improve balance and reduce the risk of falls among people with Parkinson’s disease in a Turkish study. Such balance training was found most effective when the exercise was…
Recent Posts
- When it comes to Parkinson’s, hope is not a plan, but urgent action is
- My uncle’s Parkinson’s progression changed some things, but not others
- Gene therapy shows promise for early-onset Parkinson’s in lab study
- New study finds early Parkinson’s signals in blood years before symptoms
- The nudge I needed to better manage my anxiety with Parkinson’s